RFG Advisory’s Amedisys AMED Stock Holding History

RFG Advisory’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,343	Closed	-$200K	–	480
2021 Q3	$200K	Sell	1,343 -9	-0.7%	-$1.87K	0.02%	409
2021 Q2	$331K	Buy	+1,352	New	+$355K	0.03%	333

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

RFG Advisory's AMED Position: Q4 2021 in Review

RFG Advisory sold out of Amedisys (AMED) in Q4 2021, closing a stake of 1,343 shares — an estimated $200K sold.

RFG Advisory first reported a position in AMED in Q2 2021 and held it in 2 quarters. The position peaked at $331K in Q2 2021. 324 funds tracked by Wall St. Rank hold AMED as of Q4 2021.

RFG Advisory reported no remaining Amedisys position as of Q4 2021 after selling out during the quarter.
RFG Advisory sold 1,343 Amedisys shares in Q4 2021, an estimated $200K.
RFG Advisory first reported a position in Amedisys in Q2 2021 and held it in 2 quarters.
RFG Advisory's Amedisys position peaked at $331K in Q2 2021.
324 funds tracked by Wall St. Rank held Amedisys as of Q4 2021.

Based on RFG Advisory's 13F filing for Q4 2021, filed 2 Feb 2022.